Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

1269447

USP

Fenofibrate

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid isopropyl ester

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C20H21ClO4
Numéro CAS:
49562-28-9
Poids moléculaire :
360.83
Numéro MDL:
MFCD00133314
Code UNSPSC :
41116107
ID de substance PubChem :
329749836
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

fenofibrate

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2

InChI

1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3

Clé InChI

YMTINGFKWWXKFG-UHFFFAOYSA-N

Informations sur le gène

human ... PPARA(5465)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fenofibrate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Fenofibrate Capsules
  • Fenofibrate Tablets

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

F0048005

Fenofibrate impurity A, European Pharmacopoeia (EP) Reference Standard

1269607

Fenofibrate Related Compound A, United States Pharmacopeia (USP) Reference Standard

F0048010

Fenofibrate impurity B, European Pharmacopoeia (EP) Reference Standard

1269629

Fenofibrate Related Compound C, United States Pharmacopeia (USP) Reference Standard

1269618

Fenofibrate Related Compound B, United States Pharmacopeia (USP) Reference Standard

F0048035

Fenofibrate impurity G, European Pharmacopoeia (EP) Reference Standard

1133558

Choline Fenofibrate, United States Pharmacopeia (USP) Reference Standard

PHR2864

Fenofibrate Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Warning

Mentions de danger

H373

Conseils de prudence

P260 - P314 - P501

Classification des risques

STOT RE 2 Oral

Organes cibles

Liver

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 2

1 of 2

Fenofibric acid analytical standard

Supelco

90568

Fenofibric acid

Bezafibrate ≥98%, solid

Sigma-Aldrich

B7273

Bezafibrate

Samuel Rommelaere et al.
PloS one, 9(8), e104925-e104925 (2014-08-21)
Liver is a major regulator of lipid metabolism and adaptation to fasting, a process involving PPARalpha activation. We recently showed that the Vnn1 gene is a PPARalpha target gene in liver and that release of the Vanin-1 pantetheinase in serum
Pascale Massin et al.
Ophthalmic epidemiology, 21(5), 307-317 (2014-08-19)
Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME. In this double-blind, randomized, placebo-controlled study, 110 subjects with DME not
Michel P Hermans
Diabetes & vascular disease research, 8(3), 180-189 (2011-05-18)
Microvascular complications are common in type 2 diabetes in primary care. Intensified management of glycaemia or blood pressure had little effect on microvascular complication rates in recent large trials (ADVANCE, VADT, ACCORD). In 2005, the FIELD study demonstrated a significant
Kate McKeage et al.
Drugs, 71(14), 1917-1946 (2011-09-29)
Fenofibrate is a fibric acid derivative indicated for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to nonpharmacological therapies. The lipid-modifying effects of fenofibrate are mediated by the activation of peroxisome proliferator-activated receptor-α. Fenofibrate
Wen Huang et al.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 34(4), 646-653 (2014-01-16)
The strategies to protect against the disrupted blood-brain barrier (BBB) in HIV-1 infection are not well developed. Therefore, we investigated the potential of peroxisome proliferator-activated receptor (PPAR) agonists to prevent enhanced BBB permeability induced by HIV-1-specific protein Tat. Exposure to
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique